Synthesis and biological activity of Benzoxazole containing thiazolidinedione derivatives

Archives of Pharmacal Research

Volumn 27, Issue 11, 2004, Pages 1099-1105

  Jeon, Raok ^a   Park, SoYeon ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Benzoxazole; PPAR; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; BENZOXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL; ARTICLE; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; PLASMID; SYNTHESIS;

ANIMALS; BENZOXAZOLES; CELL LINE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLASMIDS; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 16644373160     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/BF02975111     Document Type: Article

References (17)

1. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 23, 1605–1611 (2000). DOI: 10.2337/diacare.23.11.1605
2. Berger, J. and Moller, D. E., The mechanisms of action of PPARs.Ann. Rev. Med., 53, 409–435 (2002). DOI: 10.1146/annurev.med.53.082901.104018
3. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Snith, S. A., and Thurlby P. L., [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.J. Med. Chem., 37, 3977–3985 (1994). DOI: 10.1021/jm00049a017
4. Dahl-Jorgensen, K. and Brinchmann-Hansen, O., Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study.Br. Med. J., 293, 1195–1199 (1986). DOI: 10.1136/bmj.293.6556.1195
5. Defronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview.Diabetes Care, 15, 318–368 (1992). DOI: 10.2337/diacare.15.3.318
6. Defronzo, R. A., Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.Diabetes, 37, 667–687 (1988).
7. Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism.Endcrine Rev., 20, 649–688 (1999). DOI: 10.1210/er.20.5.649
8. Feldt-Rasmussen, B., Mathisesn, E., and Deckert, T., Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes.Lancet, 2, 1300–1304 (1986). DOI: 10.1016/S0140-6736(86)91433-9
9. Holman, R. R. and Turner, R. C.,Textbook of Diabetes; Pickup, J. C., Williams, G. Eds.; Blackwell Scientofic Publications: London, pp 462–476 (1991).
10. Ibrahimi, A., Teboul, L., Gaillard, D., Amir, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimardi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.Mol. Pharmacol., 46, 1070–1076 (1994).
11. Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease.Nature, 405, 421–424 (2000). DOI: 10.1038/35013000
12. Kletzien, R. F., Clark, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent.Mol. Pharmacol., 41, 393–398 (1992).
13. Lehmann, J. M., Moorre, L. B., Smith-Oliver, T. A., Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).J. Biol. Chem., 270, 12953–12956 (1995). DOI: 10.1074/jbc.270.50.30221
14. Martin, G., Schoonjans, K., Staels, B., and Aurex, J., PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes.Atheroscrelosis, 137 (Suppl), S75-S80 (1998). DOI: 10.1016/S0021-9150(97)00315-8
15. Morita, H., Mori, H., and Kobayashi, Y., Process for the production of a thiazolidine derivative. GB 2324089A (1998). Ruderman, N. B. and Scheneider, S. H., Diabetes, exercise, and atherosclerosis.Diabetes Care, 15 (Suppl. 4), 1787–1793 (1992).
16. Sohda, T., Momose, Y, Meguro, K., Kawamatsu, Y., Sugiyama, Y, and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4- thiazolidinediones.Arzneim.-Forsch., 40, 37–42 (1990).
17. Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y, Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.J. Med. Chem., 32, 421–428 (1989). DOI: 10.1021/jm00122a022